The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Enzalutamide Shows Promise in HR+ Breast Cancer

Denise Yardley, MD
Published Online: 6:42 PM, Thu December 7, 2017


Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.